ArticleScientific reports2025
Screening of SGLT2 inhibitors based on virtual screening and cellular experiments.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Molecular mechanisms and computational insights into human SGLTs: advancing toward selective SGLT1 inhibition.Frontiers in molecular biosciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
This study aims at find hit compounds as SGLT2 inhibitors through the methods of virtual screening, biological experiment, Structural similarity search and molecular docking. Computer-aided drug design techniques were used to build modelling of quantitative construct validity relationships. Three-dimensional pharmacophore model and the principle of drug properties were used to screen the compounds. The effects of lead compounds on glucose uptake were observed in 293 T cells. Further, structural similarity searches were conducted on 13 hit compounds, then molecular docking the compounds with proteins was performed. Based on virtual screening, 20 highly rated compounds as potential lead candidates for diabetes treatment were selected. Combining the results in glucose uptake assays, 13 hit compounds were identified with strong inhibitory properties against SGLT2, especially, compound 2 had the lowest glucose uptake and the best inhibition of SGLT2. The compounds were classified into 5 classes and each class has the same core skeleton. Molecular docking cleared and definite that the hit compounds had stable and efficient hydrogen-bonding interactions with SGLT2, and their binding to SGLT2 was specific. 13 hit compounds were identified with strong inhibitory properties against SGLT2, and they are likely to become new SGLT2 inhibitors to treat diabetes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.